title: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.
abstract: Advanced malignant melanoma is an aggressive malignancy with poor prognosis. Current therapeutic strategies have a modest success rate. The most promising treatment consists of a combination of chemotherapy with interferon-alpha, but complete response rates remain less than 15%. Interferon-alpha is also effective in adjuvant therapy for non-advanced melanoma treated surgically. The molecular mechanisms leading to loss of growth restraints and gain of growth-promoting functions during carcinogenesis of malignant melanoma are not understood in detail. Here, we studied 9 human melanoma cell lines with regard to growth inhibition by interferon-alpha and defects in intracellular signal transduction through the Jak-STAT pathway. In 3 cell lines, we found a complete loss of growth restraint by interferon-alpha. In all of them, different components of the Jak-STAT pathway were defective. Since signal transduction through the Jak-STAT pathway is necessary for antiviral and antiproliferative effects of interferons, we conclude that defects in this pathway may be one of the mechanisms that lead to cancer progression through loss of growth-restraining functions. Moreover, our results indicate that a subgroup of melanomas could be completely resistant to interferon-alpha and should therefore not be treated with this cytokine.
authors.affiliation: Department of Research, University Hospital Basel, Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Pansky
authors.forename: P
authors.initials: P
authors.lastname: Hildebrand
authors.forename: E
authors.initials: E
authors.lastname: Fasler-Kan
authors.forename: L
authors.initials: L
authors.lastname: Baselgia
authors.forename: S
authors.initials: S
authors.lastname: Ketterer
authors.forename: C
authors.initials: C
authors.lastname: Beglinger
authors.forename: M H
authors.initials: MH
authors.lastname: Heim
mesh_terms: D002455:Cell Division / Q000187:drug effects; D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D004268:DNA-Binding Proteins / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000633:toxicity*; D053613:Janus Kinase 1; D007621:Karyotyping; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D053633:Receptor, Interferon alpha-beta; D017471:Receptors, Interferon / Q000502:physiology; D050794:STAT1 Transcription Factor; D050795:STAT2 Transcription Factor; D050796:STAT3 Transcription Factor; D015398:Signal Transduction / Q000187:drug effects; D053634:TYK2 Kinase; D015534:Trans-Activators / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D016898:Interferon-alpha; D011506:Proteins; D017471:Receptors, Interferon; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D050795:STAT2 Transcription Factor; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D015534:Trans-Activators; D053633:Receptor, Interferon alpha-beta; D011505:Protein-Tyrosine Kinases; C507904:JAK1 protein, human; D053613:Janus Kinase 1; D053634:TYK2 Kinase; C070139:TYK2 protein, human